Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 19 October 2022, 13:01 HKT/SGT
Share:
Sirnaomics to Present Latest Developments on GalAhead(TM) Therapeutic Platform at Upcoming Industry Conferences
Sirnaomics Chief Technology Officer Dmitry Samarsky is a featured speaker at the RNA Leaders USA Congress and 18th Drug Discovery Innovation Programme

Gaithersburg, MD, USA and Suzhou BioBay, China, Oct 19, 2022 - (ACN Newswire) - Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK) a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the latest developments on GalAhead(TM), a GalNAc-RNAi therapeutic platform, and its pipeline programs, at two industry conferences in Boston: the RNA Leaders USA Congress and 18th Drug Discovery Innovation Programme. The RNA Leaders USA Congress is taking place October 18-19 at The Colonnade Hotel, and the 18th Drug Discovery Innovation Programme is taking place October 26-27 at The Westin Copley Place.

RNA Leaders USA Congress Presentation Details
Presentation Title : GalAhead(TM): a novel therapeutic GalNAc-RNAi platform to downregulate single and multiple genes
Presenter: Dmitry Samarsky, Sirnaomics Chief Technology Officer
Time/Date: 02:10pm EST on Wednesday, Oct.19, 2022.
Presentation Details:
-- Introduction to GalAhead, Sirnaomics' GalNAc-RNAi therapeutic platform
-- Validation of technology in vivo and in vitro
-- Progress report on GalAhead-based programs

18th Drug Discovery Innovation Programme Presentation Details
Presentation Title: A novel therapeutic GalNAc-RNAi platform to downregulate single and multiple genes
Presenter: Dmitry Samarsky, Sirnaomics Chief Technology Officer
Time/Date: 04:00pm EST on Wednesday, Oct. 26, 2022.
Presentation Details:
-- Introduction to GalAhead, Sirnaomics' GalNAc-RNAi therapeutic platform
-- Validation of technology in vivo and in vitro
-- Progress report on GalAhead-based programs

About Sirnaomics
Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both China and the United States, and also the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutic for its core product, STP705. Learn more at www.sirnaomics.com.

CONTACT:
Dr. Dmitry Samarsky
Chief Technology Officer, Sirnaomics
Email: DmitrySamarsky@sirnaomics.com

Investors:
Nigel Yip, MBA
Chief Financial Officer, Sirnaomics
Email: NigelYip@sirnaomics.com

Media (US):
Alexis Feinberg
Tel: +1 203 939 2225
Email: Alexis.Feinberg@westwicke.com

Media (China):
Bunny Lee
Tel: +852 3150 6707
Email: sirnaomics.hk@pordahavas.com



Topic: Press release summary Sectors: BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"  
Tuesday, November 5, 2024 10:35:00 AM
APTEXPO 2024 To Empower Asia Pacific's Fashion And Supply Chain Decision Makers For The Future  
Nov 5, 2024 09:00 HKT/SGT
Source Intelligence Evolves With C-Map: Delivering Next-Generation SaaS Platform for Compliance & Sustainability  
Nov 5, 2024 05:00 HKT/SGT
LQR House Inc. Reports 424.58% Year-Over-Year Revenue Growth in October 2024 Compared to October 2023  
Nov 4, 2024 22:00 HKT/SGT
Will New Gonow Recreational Vehicles Make It the Next Thor Industries?  
Nov 4, 2024 20:00 HKT/SGT
HEROWORKS Embarks on Global Expansion with Hotel Revenue Management System  
Nov 4, 2024 17:00 HKT/SGT
JBM Healthcare Limited Issues Positive Profit Alert  
Nov 4, 2024 15:00 HKT/SGT
Asahi Kasei and Honda Sign Shareholders' Agreement to Convert Existing Asahi Kasei Subsidiary into Joint Venture for Production of Lithium-ion Battery Separators in Canada  
Monday, November 4, 2024 1:12:00 PM
GTJAI was selected into the first batch of qualified securities companies for the 'Cross-boundary Wealth Management Pilot Scheme'  
Nov 4, 2024 10:58 HKT/SGT
With interest rate cuts taking effect, CWT hopes to take advantage of the favorable macro trend  
Nov 4, 2024 09:19 HKT/SGT
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: